Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Julia Pamies Besora"'
Autor:
Carles Moliner-Abós, Diana Mojón Álvarez, Mercedes Rivas-Lasarte, Laia Carla Belarte, Julia Pamies Besora, Eduard Solé-González, Paula Fluvià-Brugues, Isabel Zegrí-Reiriz, Laura López López, Vicens Brossa, Maria José Pirla, Nuria Mesado, Sonia Mirabet, Eulàlia Roig, Jesús Álvarez-García
Publikováno v:
Frontiers in Physiology, Vol 12 (2021)
IntroductionSacubitril/valsartan (SV) promotes cardiac remodeling and improves prognosis in patients with heart failure (HF). However, the response to the drug may vary between patients and its implementation in daily clinical practice has been slowe
Externí odkaz:
https://doaj.org/article/8c617b26f72d41d9b6ba040bc4f52279
Autor:
Mercedes Rivas-Lasarte, Nuria Mesado, Jesús Álvarez-García, Isabel Zegrí-Reiriz, Carles Moliner-Abós, Diana Mojón Álvarez, V. Brossa, L. Lopez, Sonia Mirabet, Eduard Solé-González, Eulalia Roig, Paula Fluvià-Brugues, Julia Pamies Besora, Maria Jose Pirla, Laia Carla Belarte
Publikováno v:
Frontiers in Physiology, Vol 12 (2021)
Frontiers in Physiology
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Frontiers in Physiology
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
IntroductionSacubitril/valsartan (SV) promotes cardiac remodeling and improves prognosis in patients with heart failure (HF). However, the response to the drug may vary between patients and its implementation in daily clinical practice has been slowe
Autor:
Carles Moliner-Abós, V. Brossa, Julia Pamies Besora, Eduard Solé-González, Paula Fluvià-Brugues, L. Lopez, Eulalia Roig, Nuria Mesado, Jesús Álvarez-García, Sonia Mirabet, Maria Jose Pirla, Mercedes Rivas-Lasarte
Publikováno v:
Cardiovascular drugs and therapy. 33(3)
Sacubitril/valsartan reduced heart failure (HF) admissions and cardiovascular mortality in the PARADIGM-HF trial. However, real-life studies are scarce comparing daily practice patients with those of the trial. The aim of our study was to analyze the